Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)
NCT ID: NCT00807053
Last Updated: 2016-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
480 participants
INTERVENTIONAL
2007-04-30
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily
Ciclesonide HFA
75 mcg Ciclesonide HFA versus Placebo
2
Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily
Ciclesonide HFA
150 mcg Ciclesonide HFA versus Placebo
3
Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily
Ciclesonide HFA
300 mcg Ciclesonide HFA versus Placebo
4
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ciclesonide HFA
75 mcg Ciclesonide HFA versus Placebo
Ciclesonide HFA
150 mcg Ciclesonide HFA versus Placebo
Ciclesonide HFA
300 mcg Ciclesonide HFA versus Placebo
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. General good health, and free of any concomitant conditions or treatment that could interfere with study conduct,influence the interpretation of study observations/results, or put the patient at increases risk during the trial
3. A history of SAR to relevant seasonal allergen for a minimum of two years immediately preceding the study season. The SAR must have been of sufficient severity to have required treatment (continuous or intermittent) in the past and in the investigator´s judgment - is expected to require treatment throughout the entire study period
4. A demonstrated sensitivity to grass or tree pollen known to induce SAR through a standard skin prick test. A positive test is defined as a wheal diameter at least 3 mm larger than the control wheal for the skin prick test. Documentation of a positive result 12 months prior to screening is acceptable
5. Female is of child-bearing potential and is currently taking and will continue to use a medically reliable method of contraception for the entire study duration (e.g. oral, injectable, trans-cutaneous or implantable contraceptives or intrauterine devices or double-barrier protection). Women of childbearing potential, or less than 1 year postmenopausal, will require a negative pregnancy test at the Screnning Visit (B0) as well as at last on-treatment (T2)
6. Capable of understanding the requirements, risks and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and compliance with all study requirements (visits, record-keeping, etc.)
Exclusion Criteria
2. History of physical findings of nasal pathology, including nasal polyps (within the last 60 days) or other clinically significant respiratory tract malformations, recent nasal biopsy (within the last 60 days), nasal trauma, or surgery and atrophic rhinitis or rhinitis medicamentosa (within the last 60 days)
3. Participation in any investigational drug trial within the 30 days preceding the Screening Visit (B0)
4. A known hypersensitivity to any corticosteroid or any of the excipients in the formulation
5. History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, the common cold, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)) within the 14 days preceding the Screening Visit (B0), or development of a respiratory infection during the Baseline Period.
6. History of alcohol or drug abuse within the preceding two years
7. History of a positive test of HIV, hepatitis B or hepatitis C
8. Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of ß-agonists and any controller drugs (e.g., theophylline, leukotriene antagonists, etc.; intermittent use (less than or equal to 3 uses per week) of inhaled short acting ß-agonists is acceptable
9. Plans to travel outside the study area (the known pollen area for the investigative site) for two or more consecutive days OR 5 or more days total starting from 7 days prior to Randomization Visit (T0) until the final Treatment Visit (T2)
10. Use of any prohibited concomitant medications within the prescribed (per protocol) time since last dose period prior to the Screening Visit (B0) and during entire treatment duration.
11. Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit (B0). Low doses of antibiotics taken for prophylaxis are permitted if the therapy was started prior to the Screening Visit (B0) AND is expected to continue throughout the trial.
12. Initiation of immunotherapy during the study period or dose escalation during the study period. However, initiation of immunotherapy 90 days or more prior to the Screening Visit (B0) AND use of a stable (maintenance) dose (30 days or more) may be considered for inclusion.
13. Previous participation in an intranasal ciclesonide HFA nasal aerosol study.
14. Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding the Screening Visit (B0).
15. Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone or equivalent within 30 days prior to the Screening Visit (B0); use of a topical hydrocortisone or equivalent in any concentration covering greater than 20% of the body surface; or presence of an underlying condition (as judged by the investigator) that can reasonably be expected to require treatment with such preparations during the course of the study.
16. Initiation of pimecrolimus cream 1% or greater or tacrolimus ointment 0.03% or greater during the study period or planned dose escalation during the study period. However, initiation of these creams/ointments 30 days or more prior to the Screening Visit (B0) AND use of a stable (maintenance) dose during the study period may be considered for inclusion.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca AstraZeneca
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altana/Nycomed
Mission Viejo, California, United States
Altana/Nycomed
Orange, California, United States
Altana/Nycomed
San Diego, California, United States
Altana/Nycomed
Colorado Springs, Colorado, United States
Altana/Nycomed
Denver, Colorado, United States
Altana/Nycomed
Gainsville, Georgia, United States
Altana/Nycomed
Savannah, Georgia, United States
Altana/Nycomed
Stockbridge, Georgia, United States
Altana/Nycomed
Indianapolis, Indiana, United States
Altana/Nycomed
Overland Park, Kansas, United States
Altana/Nycomed
Bethesda, Maryland, United States
Altana/Nycomed
Minneapolis, Minnesota, United States
Altana/Nycomed
St Louis, Missouri, United States
Altana/Nycomed
Lincoln, Nebraska, United States
Altana/Nycomed
Papillion, Nebraska, United States
Altana/Nycomed
Skillman, New Jersey, United States
Altana/Nycomed
West Brick, New Jersey, United States
Altana/Nycomed
Raleigh, North Carolina, United States
Altana/Nycomed
Ashland, Oregon, United States
Altana/Nycomed
Medford, Oregon, United States
Altana/Nycomed
Portland, Oregon, United States
Altana/Nycomed
Blue Bell, Pennsylvania, United States
Altana/Nycomed
Pittsburgh, Pennsylvania, United States
Altana/Nycomed
Upland, Pennsylvania, United States
Altana/Nycomed
Charleston, South Carolina, United States
Altana/Nycomed
Austin, Texas, United States
Altana/Nycomed
New Braunfels, Texas, United States
Altana/Nycomed
San Antonio, Texas, United States
Altana/Nycomed
Draper, Utah, United States
Altana/Nycomed
Burke, Virginia, United States
Altana/Nycomed
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BY9010/M1-602
Identifier Type: -
Identifier Source: org_study_id